{
  "trial_id": "NCT00379912",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "A bone marrow (BM) aspirate and biopsy that demonstrates MDS with less than 11% blasts.",
      "label": "met"
    },
    {
      "criterion": "Conventional metaphase cytogenetics done within 90 days prior to registration for screening.",
      "label": "met"
    },
    {
      "criterion": "Central pathology review, correlative submission and confirmation of diagnosis is required prior to initiation of therapy (see Study Procedure Manual for details of submission). The FAB and WHO classification of MDS and the IPSS score will be determined at time of central pathology review.",
      "label": "met"
    },
    {
      "criterion": "Correlative marrow aspirate obtained.",
      "label": "met"
    },
    {
      "criterion": "A transfusion dependent anemia (defined by a history of two or more episodes of transfusion within a period of 8 weeks).",
      "label": "met"
    },
    {
      "criterion": "An untransfused hemoglobin < 10 gm/dl measured on at least two occasions more than 7 days apart in the month prior to randomization.",
      "label": "met"
    },
    {
      "criterion": "Has not received prior erythropoietin and has a serum erythropoietin level > 200 IU/L within 14 days of randomization.",
      "label": "met"
    },
    {
      "criterion": "Adequate iron status defined as serum ferritin > 20 ng/ml and transferrin saturation of > 30% within 90 days prior to randomization.",
      "label": "met"
    },
    {
      "criterion": "Symptoms attributed to the anemia with hemoglobin < 11 g/dL.",
      "label": "met"
    },
    {
      "criterion": "Folate and Vitamin B12 levels within normal limits within 90 days prior to randomization.",
      "label": "met"
    },
    {
      "criterion": "Life expectancy > 6 months as judged by the treating investigator.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "No history of (within 6 months) cerebrovascular accident ([CVA] includes ischemic, embolic, and hemorrhagic), transient ischemic attack (TIA), myocardial ischemia (includes Unstable Angina, Q wave Myocardial Infarction [QwMI], and non-Q wave Myocardial Infarction [NQMI]), or other arterial thrombosis.",
      "label": "not_met"
    },
    {
      "criterion": "No known history of intolerance to erythropoietic agents.",
      "label": "unknown"
    },
    {
      "criterion": "No prior intensive cytotoxic chemotherapy for a myeloid malignancy including MDS.",
      "label": "not_met"
    }
  ],
  "notes": "The patient has symptoms attributed to anemia with hemoglobin < 11 g/dL and adequate iron status. However, they have a history of intolerance to erythropoietic agents which is unknown.",
  "_meta": {
    "topic_id": "32",
    "trial_id": "NCT00379912",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}